Bernd Robert Seizinger Acquires 60,000 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Bernd Robert Seizinger purchased 60,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were acquired at an average price of C$1.14 per share, for a total transaction of C$68,400.00. Following the completion of the transaction, the director owned 526,991 shares in the company, valued at C$600,769.74. The trade was a 12.85% increase in their ownership of the stock.

Bernd Robert Seizinger also recently made the following trade(s):

• On Thursday, February 12th, Bernd Robert Seizinger bought 40,000 shares of Oncolytics Biotech stock. The stock was purchased at an average cost of C$1.17 per share, with a total value of C$46,800.00.

Oncolytics Biotech Stock Performance

Oncolytics Biotech Inc. has a 52 week low of C$0.44 and a 52 week high of C$2.08. The business’s 50-day simple moving average is C$14.90 and its 200 day simple moving average is C$13.02. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, analysts predict that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.